Capture of endothelial cells under flow using immobilized vascular endothelial growth factor

Biomaterials

Volumn 51, Issue , 2015, Pages 303-312

  Smith, Randall J ^b   Koobatian, Maxwell T ^c   Shahini, Aref ^a   Swartz, Daniel D ^c,d   Andreadis, Stelios T ^a,b,c  

^a State University of New York   (United States)

^b University at Buffalo SUNY   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Immobilized growth factor; Shear stress; Vascular grafts; VEGF

Indexed keywords

AMINO ACIDS; BIOACTIVITY; CELL CULTURE; ENDOTHELIAL CELLS; FIBROBLASTS; FLOW OF FLUIDS; GRAFTS; POLYSACCHARIDES; SHEAR STRESS; STEM CELLS;

GROWTH FACTOR; HEPARIN BINDING DOMAINS; HUMAN DERMAL FIBROBLASTS; HUMAN UMBILICAL VEINS; MESENCHYMAL STEM CELL; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR GRAFTS; VEGF;

CELL ENGINEERING;

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POLYLYSINE; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 2; IMMOBILIZED PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD VESSEL GRAFT; CELL PROLIFERATION; ENDOTHELIUM CELL; FLOW RATE; HAIR FOLLICLE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; SHEAR STRENGTH; SHEAR STRESS; UMBILICAL VEIN; UMBILICAL VEIN ENDOTHELIAL CELL; 3T3 CELL LINE; ANIMAL; CYTOLOGY; DRUG EFFECTS; FLOW KINETICS; LAB ON A CHIP; MECHANICAL STRESS; METABOLISM; SHEEP;

OVIS;

ANIMALS; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMOBILIZED PROTEINS; LAB-ON-A-CHIP DEVICES; MICE; NIH 3T3 CELLS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RHEOLOGY; SHEEP; STRESS, MECHANICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924863718     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.025     Document Type: Article

References (90)

1. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. Seifalian A.M., Tiwari A., Hamilton G., Salacinski H.J. Improving the clinical patency of prosthetic vascular and coronary bypass grafts: the role of seeding and tissue engineering. Artif Organs 2002, 26:307-320.
3. Veith F.J., Moss C.M., Sprayregen S., Montefusco C. Preoperative saphenous venography in arterial reconstructive surgery of the lower extremity. Surgery 1979, 85:253-256.
4. Gaudino M., Cellini C., Pragliola C., Trani C., Burzotta F., Schiavoni G., et al. Arterial versus venous bypass grafts in patients with in-stent restenosis. Circulation 2005, 112:I265-I269.
5. Gao J., Niklason L., Langer R. Surface hydrolysis of poly(glycolic acid) meshes increases the seeding density of vascular smooth muscle cells. JBiomed Mater Res 1998, 42:417-424.
6. Gong Z., Niklason L.E. Blood vessels engineered from human cells. Trends Cardiovasc Med 2006, 16:153-156.
7. Gong Z., Niklason L.E. Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs). FASEB J Off Publ Fed Am Soc Exp Biol 2008, 22:1635-1648.
8. Huang A.H., Niklason L.E. Engineering biological-based vascular grafts using a pulsatile bioreactor. JVis Exp 2011, 52(2646).
9. McKee J.A., Banik S.S., Boyer M.J., Hamad N.M., Lawson J.H., Niklason L.E., et al. Human arteries engineered invitro. EMBO Rep 2003, 4:633-638.
10. Niklason L.E., Gao J., Abbott W.M., Hirschi K.K., Houser S., Marini R., et al. Functional arteries grown invitro. Science 1999, 284:489-493.
11. Poh M., Boyer M., Solan A., Dahl S.L., Pedrotty D., Banik S.S., et al. Blood vessels engineered from human cells. Lancet 2005, 365:2122-2124.
12. Prabhakar V., Grinstaff M.W., Alarcon J., Knors C., Solan A.K., Niklason L.E. Engineering porcine arteries: effects of scaffold modification. JBiomed Mater Res Part A 2003, 67:303-311.
13. L'Heureux N., Dusserre N., Konig G., Victor B., Keire P., Wight T.N., et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 2006, 12:361-365.
14. L'Heureux N., Dusserre N., Marini A., Garrido S., de la Fuente L., McAllister T. Technology insight: the evolution of tissue-engineered vascular grafts-from research to clinical practice. Nat Clin Pract Cardiovasc Med 2007, 4:389-395.
15. L'Heureux N., Germain L., Labbe R., Auger F.A. Invitro construction of a human blood vessel from cultured vascular cells: a morphologic study. JVasc Surg 1993, 17:499-509.
16. L'Heureux N., McAllister T.N., de la Fuente L.M. Tissue-engineered blood vessel for adult arterial revascularization. NEngl J Med 2007, 357:1451-1453.
17. L'Heureux N., Paquet S., Labbe R., Germain L., Auger F.A. Acompletely biological tissue-engineered human blood vessel. FASEB J Off Publ Fed Am Soc Exp Biol 1998, 12:47-56.
18. Quint C., Arief M., Muto A., Dardik A., Niklason L.E. Allogeneic human tissue-engineered blood vessel. JVasc Surg 2011, 55(3):790-798.
19. Dahl S.L., Kypson A.P., Lawson J.H., Blum J.L., Strader J.T., Li Y., et al. Readily available tissue-engineered vascular grafts. Sci Transl Med 2011, 3. 68ra9.
20. Syedain Z.H., Meier L.A., Lahti M.T., Johnson S.L., Tranquillo R.T. Implantation of completely biological engineered grafts following decellularization into the sheep femoral artery. Tissue Eng Part A 2014, 20:1726-1734.
21. Wystrychowski W., McAllister T.N., Zagalski K., Dusserre N., Cierpka L., L'Heureux N. First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access. JVasc Surg 2013, 60(5):1353-1357.
22. Peng H., Schlaich E.M., Row S., Andreadis S.T., Swartz D.D. Anovel ovine exvivo arteriovenous shunt model to test vascular implantability. Cells Tissues Organs 2012, 195:108-121.
23. Wu W., Allen R.A., Wang Y. Fast-degrading elastomer enables rapid remodeling of a cell-free synthetic graft into a neoartery. Nat Med 2012, 18:1148-1153.
24. Pratt E.D., Huang C., Hawkins B.G., Gleghorn J.P., Kirby B.J. Rare cell capture in microfluidic devices. Chem Eng Sci 2011, 66:1508-1522.
25. Angelos M.G., Brown M.A., Satterwhite L.L., Levering V.W., Shaked N.T., Truskey G.A. Dynamic adhesion of umbilical cord blood endothelial progenitor cells under laminar shear stress. Biophys J 2010, 99:3545-3554.
26. Plouffe B.D., Kniazeva T., Mayer J.E., Murthy S.K., Sales V.L. Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine. FASEB J Off Publ Fed Am Soc Exp Biol 2009, 23:3309-3314.
27. Markway B.D., McCarty O.J.T., Marzec U.M., Courtman D.W., Hanson S.R., Hinds M.T. Capture of flowing endothelial cells using surface-immobilized anti-kinase insert domain receptor antibody. Tissue Eng Part C Methods 2008, 14:97-105.
28. Irace C., Carallo C., De Franceschi M.S., Scicchitano F., Milano M., Tripolino C., et al. Human common carotid wall shear stress as a function of age and gender: a 12-year follow-up study. Age 2012, 34:1553-1562.
29. Anderson S.M., Chen T.T., Iruela-Arispe M.L., Segura T. The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF. Biomaterials 2009, 30:4618-4628.
30. Chen T.T., Luque A., Lee S., Anderson S.M., Segura T., Iruela-Arispe M.L. Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. JCell Biol 2010, 188:595-609.
31. Fan V.H., Tamama K., Au A., Littrell R., Richardson L.B., Wright J.W., et al. Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells (Dayton, Ohio) 2007, 25:1241-1251.
32. Leclerc C., Brose C., Nouze C., Leonard F., Majlessi L., Becker S., et al. Immobilized cytokines as biomaterials for manufacturing immune cell based vaccines. JBiomed Mater Res Part A 2008, 86:1033-1040.
33. Mann B.K., Schmedlen R.H., West J.L. Tethered-TGF-beta increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 2001, 22:439-444.
34. Platt M.O., Roman A.J., Wells A., Lauffenburger D.A., Griffith L.G. Sustained epidermal growth factor receptor levels and activation by tethered ligand binding enhances osteogenic differentiation of multi-potent marrow stromal cells. JCell Physiol 2009, 221:306-317.
35. Yu L.M., Wosnick J.H., Shoichet M.S. Miniaturized system of neurotrophin patterning for guided regeneration. JNeurosci Methods 2008, 171:253-263.
36. Zisch A.H., Schenk U., Schense J.C., Sakiyama-Elbert S.E., Hubbell J.A. Covalently conjugated VEGF-fibrin matrices for endothelialization. JControl Release Off J Control Release Soc 2001, 72:101-113.
37. Geer D.J., Swartz D.D., Andreadis S.T. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing invitro and invivo. Am J Pathol 2005, 167:1575-1586.
38. Hu X., Neoh K.G., Zhang J., Kang E.T., Wang W. Immobilization strategy for optimizing VEGF's concurrent bioactivity towards endothelial cells and osteoblasts on implant surfaces. Biomaterials 2012, 33:8082-8093.
39. Sasaki M., Inoue M., Katada Y., Taguchi T. The effect of VEGF-immobilized nickel-free high-nitrogen stainless steel on viability and proliferation of vascular endothelial cells. Colloids and Surfaces B Biointerfaces 2012, 92:1-8.
40. Liang M.S., Andreadis S.T. Engineering fibrin-binding TGF-beta1 for sustained signaling and contractile function of MSC based vascular constructs. Biomaterials 2011, 32:8684-8693.
41. Wijelath E.S., Rahman S., Namekata M., Murray J., Nishimura T., Mostafavi-Pour Z., et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006, 99:853-860.
42. Benoit D.S., Anseth K.S. Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation. Acta Biomater 2005, 1:461-470.
43. Schroeder-Tefft J.A., Bentz H., Estridge T.D. Collagen and heparin matrices for growth factor delivery. JControl Release 1997, 49:291-298.
44. Yamaguchi N., Kiick K.L. Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels. Biomacromolecules 2005, 6:1921-1930.
45. Maharaj A.S.R., D'Amore P.A. Roles for VEGF in the adult. Microvasc Res 2007, 74:100-113.
46. Ho Q.T., Kuo C.J. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007, 39:1349-1357.
47. Otrock Z.K., Makarem J.A., Shamseddine A.I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007, 38:258-268.
48. Ng Y.-S., Krilleke D., Shima D.T. VEGF function in vascular pathogenesis. Exp Cell Res 2006, 312:527-537.
49. Li X., Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 2001, 33:421-426.
50. Ferrara N. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
51. Klagsbrun M., D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine & Growth Factor Rev 1996, 7:259-270.
52. Klagsbrun M., Soker S. VEGF/VPF: the angiogenesis factor found? 1993, 699-702.
53. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326.
54. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187:1579-1586.
55. Tischer E., Gospodarowicz D., Mitchell R., Silva M., Schilling J., Lau K., et al. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989, 165:1198-1206.
56. Bikfalvi A., Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002, 23:576-582.
57. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000, 11:617-624.
58. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999, 56:794-814.
59. Korpelainen E.I., Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998, 10:159-164.
60. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
61. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (New York, NY) 1989, 246:1309-1312.
62. Folkman J., Klagsbrun M. Angiogenic factors. Science (New York, NY) 1987, 235:442-447.
63. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. JBiol Chem 1996, 271:7788-7795.
64. Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. JBiol Chem 1992, 267:6093-6098.
65. Nakamura S., Kubo T., Ijima H. Heparin-conjugated gelatin as a growth factor immobilization scaffold. JBiosci Bioeng 2013, 115:562-567.
66. Sharon J.L., Puleo D.A. Immobilization of glycoproteins, such as VEGF, on biodegradable substrates. Acta Biomater 2008, 4:1016-1023.
67. Maile L.A., Busby W.H., Sitko K., Capps B.E., Sergent T., Badley-Clarke J., et al. The heparin binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol Endocrinol (Baltimore, Md) 2006, 20:881-892.
68. Mitsi M., Hong Z., Costello C.E., Nugent M.A. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. Biochemistry 2006, 45:10319-10328.
69. Ricard-Blum S., Beraud M., Raynal N., Farndale R.W., Ruggiero F. Structural requirements for heparin/heparan sulfate binding to type V collagen. JBiol Chem 2006, 281:25195-25204.
70. Wijelath E.S., Murray J., Rahman S., Patel Y., Ishida A., Strand K., et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002, 91:25-31.
71. Yamashita H., Beck K., Kitagawa Y. Heparin binds to the laminin alpha4 chain LG4 domain at a site different from that found for other laminins. JMol Biol 2004, 335:1145-1149.
72. Liu J.Y., Peng H.F., Andreadis S.T. Contractile smooth muscle cells derived from hair-follicle stem cells. Cardiovasc Res 2008, 79:24-33.
73. Swartz D.D., Russell J.A., Andreadis S.T. Engineering of fibrin-based functional and implantable small-diameter blood vessels. Am J Physiol Heart Circ Physiol 2005, 288:H1451-H1460.
74. Smith P.K., Mallia A.K., Hermanson G.T. Colorimetric method for the assay of heparin content in immobilized heparin preparations. Anal Biochem 1980, 109:466-473.
75. Fröhlich E., Bonstingl G., Höfler A., Meindl C., Leitinger G., Pieber T.R., et al. Comparison of two invitro systems to assess cellular effects of nanoparticles-containing aerosols. Toxicol Vitro 2013, 27-360:409-417.
76. Barrantes A., Santos O., Sotres J., Arnebrant T. Influence of pH on the build-up of poly-L-lysine/heparin multilayers. JColloid Interface Sci 2012, 388:191-200.
77. Dayanir V., Meyer R.D., Lashkari K., Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. JBiol Chem 2001, 276:17686-17692.
78. Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99-106.
79. Kim S., von Recum H. Endothelial stem cells and precursors for tissue engineering: cell source, differentiation, selection, and application. Tissue Eng Part B Rev 2008, 14:133-147.
80. DeLong S.A., Moon J.J., West J.L. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. Biomaterials 2005, 26:3227-3234.
81. Gobin A.S., West J.L. Effects of epidermal growth factor on fibroblast migration through biomimetic hydrogels. Biotechnol Prog 2003, 19:1781-1785.
82. Gobin A.S., West J.L. Cell migration through defined, synthetic ECM analogs. FASEB J Off Publ Fed Am Soc Exp Biol 2002, 16:751-753. Epub 2002 Mar 26.
83. Yu J., Wang A., Tang Z., Henry J., Li-Ping Lee B., Zhu Y., et al. The effect of stromal cell-derived factor-1alpha/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration. Biomaterials 2012, 33:8062-8074.
84. Lee K.W., Johnson N.R., Gao J., Wang Y. Human progenitor cell recruitment via SDF-1alpha coacervate-laden PGS vascular grafts. Biomaterials 2013, 34:9877-9885.
85. Huang J., Tan Y., Tang Q., Liu X., Guan X., Feng Z., et al. Ahigh-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes. Cytotechnology 2010, 62:61-71.
86. Cunningham S.A., Tran T.M., Arrate M.P., Brock T.A. Characterization of vascular endothelial cell growth factor interactions with the kinase insert domain-containing receptor tyrosine kinase. A real time kinetic study. JBiol Chem 1999, 274:18421-18427.
87. Nakayama M., Berger P. Coordination of VEGF receptor trafficking and signaling by coreceptors. Exp Cell Res 2013, 319:1340-1347.
88. Eichmann A., Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol 2012, 24:188-193.
89. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011, 437:169-183.
90. Suzuki Y., Yamamoto K., Ando J., Matsumoto K., Matsuda T. Arterial shear stress augments the differentiation of endothelial progenitor cells adhered to VEGF-bound surfaces. Biochem Biophys Res Commun 2012, 423:91-97.